Image2_The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis.JPEG
Background and Aims: Activation of the inflammasome NLRP3 (NOD-, LRR- and pyrin domain containing 3) contributes to the development of non-alcoholic fatty liver disease (NAFLD) and progression to non-alcoholic steatohepatitis (NASH). Therefore, this study explored the therapeutic effects of a novel and selective NLRP3 antagonist in a murine dietary model of NASH.
Methods: Groups of 12-week-old ApoE-/- mice were fed ad lib for 7 weeks with a methionine/choline deficient (MCD) and western diet (WD). After 3 weeks of diet-induced injury, mice were injected i. p. with the NLRP3 antagonist IFM-514 (100 mg/kg body weight) or vehicle (0.5% carmellose) every day, 5 days/week for a further 4 weeks. Several markers of inflammation, fibrosis and steatosis were evaluated. Whole transcriptome sequencing and panel RNA expression analysis (NanoString) were performed.
Results: IFM-514 inhibited IL-1β production in mice challenged with 20 mg/kg lipopolysaccharide, and in mouse and human inflammatory cells in vitro. IFM-514 inhibited hepatic inflammation in the in vivo non-alcoholic steatohepatitis model assessed by H&E staining and in the hepatic gene expression of inflammasome-related proinflammatory cytokines. This effect was associated with significant reduction in caspase-1 activation. Similarly, IFM-514 was efficacious in vivo in MDC-fed ApoE-/- mice, markedly reducing portal pressure, Sirius red staining and 4-hydroxyproline content compared to vehicle-treated mice. Moreover, IFM-514 significantly reduced hepatic steatosis in MCD-fed ApoE-/- mice, as evidenced by NAFLD scores, oil red O staining, hepatic triglycerides and gene expression. In WD treated animals, similar trends in inflammation and fibrosis were observed, although not sufficient IFM-514 levels were reached.
Conclusion: Overall, IFM-514 reduced liver inflammation and fibrosis, with mild effects on liver steatosis in experimental murine NASH. Blocking of NLRP3 may be an attractive therapeutic approach for NASH patients.
History
References
- https://doi.org//10.1074/jbc.M114.573659
- https://doi.org//10.1111/j.1600-0676.1996.tb00697.x
- https://doi.org//10.1053/j.gastro.2015.04.043
- https://doi.org//10.1016/j.cellsig.2015.02.025
- https://doi.org//10.1074/jbc.M114.550624
- https://doi.org//10.1152/ajpgi.00361.2018
- https://doi.org//10.1074/jbc.M109.099333
- https://doi.org//10.1016/j.cell.2017.12.013
- https://doi.org//10.1038/nrd3800
- https://doi.org//10.1038/nature08938
- https://doi.org//10.1186/s12967-015-0552-7
- https://doi.org//10.1002/hep.27117
- https://doi.org//10.1172/JCI32703
- https://doi.org//10.1038/nature10809
- https://doi.org//10.1194/jlr.M034876
- https://doi.org//10.1084/jem.20171419
- https://doi.org//10.1002/hep.20701
- https://doi.org//10.1111/j.1440-1746.2008.05543.x
- https://doi.org//10.3748/wjg.v21.i39.11088
- https://doi.org//10.1038/nrd.2018.97
- https://doi.org//10.1016/S1097-2765%2802%2900599-3
- https://doi.org//10.1186/s12876-014-0208-8
- https://doi.org//10.1016/j.jhep.2017.01.022
- https://doi.org//10.12688/F1000RESEARCH.8614.1
- https://doi.org//10.1056/NEJMoa1707914
- https://doi.org//10.1001/jama.2015.5370
- https://doi.org//10.1016/j.cmet.2009.09.006
- https://doi.org//10.1152/ajpgi.00063.2016
- https://doi.org//10.1038/srep12931
- https://doi.org//10.1016/j.cell.2010.01.040
- https://doi.org//10.1172/JCI28898
- https://doi.org//10.1073/pnas.1100255108
- https://doi.org//10.1038/nrgastro.2015.94
- https://doi.org//10.1038/nm.2279
- https://doi.org//10.1053/j.gastro.2010.09.038
- https://doi.org//10.1016/j.jhep.2018.08.011
- https://doi.org//10.1002/hep.26592
- https://doi.org//10.1007/s00109-014-1170-1
CC BY 4.0